Clinical trials: DENGUE
Viral Infection
Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
The objective is to evaluate the safety and tolerability of a single-ascending oral dose of UV-4B in healthy subjects and to determine pharmacokinetic parameters describing absorption and elimination following a single dose of…
- Trial name
- UV (NCT02061358)
- Testing
- UV-4B 3 mg, UV-4B 10 mg, UV-4B 30 mg
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Dengue
Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults
Dengue viruses can cause dengue fever and other more serious illnesses. The purpose of this study is to evaluate the safety and immune response to a dengue virus vaccine.
- Trial name
- NCT01931176
- Testing
- rDEN2Δ30-7169 vaccine
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
Serological Study of Dengue and Characterization of Immune Response in Ten Endemic and Non-Endemic Cities in Mexico
Background: Dengue continues to be a high priority disease for public health in tropical and subtropical countries, where vector control measures have not had the expected impact on transmission.
- Trial name
- NCT04947111
- Testing
- Estimate the distribution of antibodies by serotype by Dengue virus in areas of low and high incidence of dengue
- Where
- Mexico
- Volunteers
- 1,960 people, healthy volunteers welcome
- Sponsor
- Mexican Society of Public Health
Knowledge, Attitudes, Practice
Effectiveness of iDEAL in Improving the Knowledge, Attitude, Practice, Environmental Cleanliness Index and Dengue Index
Background Dengue is a mosquito-borne viral disease caused by four distinct but closely related dengue virus (DENV). The incidence of dengue has grown dramatically worldwide in recent decades, with cases reported to WHO increased…
- Trial name
- iDEAL (NCT05863026)
- Testing
- THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)
- Where
- Malaysia
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Universiti Putra Malaysia
West Nile Fever Encephalitis
Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults
West Nile (WN) virus infection is an emerging disease; WN infection may lead to paralysis, coma, and death. The purpose of this study is to test the safety of and immune response to a WN vaccine in healthy adults.
- Trial name
- NCT00094718
- Testing
- WN/DEN4-3'delta30
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Dengue Fever
Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
The aim of the study was to evaluate a compressed dosing schedule and the immunologic effects of co-administration of a CYD dengue vaccine with a licensed flavivirus (FV) with Japanese encephalitis (JE) vaccine.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01943825
- Testing
- CYD Dengue Vaccine, Japanese Encephalitis Vaccine
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00270699
- Testing
- rDEN4delta30-200,201
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant
The potential synergistic effect of administering 2 dengue vaccine candidates that were previously shown to be safe and immunogenic in humans will be evaluated in this study.
- Trial name
- NCT03110952
- Testing
- TDENV-PIV, TDENV-F17
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Healthy
A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)
The purpose of this study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue…
- Trial name
- NCT07013487
- Testing
- V181
- Where
- 41 sites in Indonesia, Malaysia and 5 more
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
GLS-5700 in Dengue Virus-Naïve Adults
The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus.
- Trial name
- NCT02809443
- Testing
- GLS-5700
- Where
- 3 sites in United States, Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Dengue, Dengue Hemorrhagic Fever
Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers
The aim of the study was to assess whether the second CYD dengue vaccination could be administered concomitantly with the booster vaccination of a pediatric combination vaccine (Pentaxim™) during the same day visit but in 2…
- Trial name
- NCT01411241
- Testing
- Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus, DTaP IPV//Hib vaccine, Measles, mumps, and rubella vaccine
- Where
- 4 sites in Mexico
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue
Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world.
- Trial name
- NCT01072786
- Testing
- TetraVax-DV Vaccine-Admixture 1, TetraVax-DV Vaccine-Admixture 2, TetraVax-DV Vaccine-Admixture 3
- Where
- 4 sites in United States
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Dengue Vaccines
This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among Household Members Aged 6 Months to 50 Years of Selected Communities in Latin America and Southeast Asia
The purpose of this study is to describe the burden of DENV illness among household members aged 6 months to 50 years of selected communities in Latin America and Southeast Asia.
- Trial name
- NCT02766088
- Testing
- Blood sample collection
- Where
- 2 sites in Mexico, Philippines
- Volunteers
- 1,750 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Arbovirus Disease, Zika
Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu
The Pacific region is facing several emerging and neglected diseases notably mosquito-borne diseases as malaria or arboviroses among which dengue, Ross River, chikungunya and Zika.
- Conditions
- Arbovirus Disease, Zika, Dengue, Ross River
- Trial name
- PIANO (NCT05153018)
- Testing
- Blood collection
- Where
- 4 sites in Vanuatu
- Volunteers
- 1,122 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Dengue
Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30
This study will evaluate the ability of a single dose of the live attenuated recombinant tetravalent dengue vaccine TetraVax-DV-TV005 (referred to as TV005) to protect against infection with rDEN3Δ30, an attenuated DENV-3, when…
- Trial name
- NCT02873260
- Testing
- TetraVax-DV-TV005, rDEN3Δ30
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy, Zika
GLS-5700 in Dengue Virus Seropositive Adults
The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus.
- Trial name
- NCT02887482
- Testing
- GLS-5700
- Where
- 3 sites in Puerto Rico
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Dengue
Effectiveness of a Online Education Material to Improve Dengue Knowledge and Health-Seeking Intention
Dengue is an endemic infectious disease in Malaysia. Delays in seeking treatment and improper self-care contribute to dengue complications and mortality.
- Trial name
- NCT05661877
- Testing
- DengueAid mobile application, MyHealth website
- Where
- Malaysia
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- University of Malaya
Arbovirus Infections
Spatial Repellents for Aedes-borne Virus Control in Sri Lanka
The primary objective of the study is to demonstrate and quantify the protective efficacy (PE) of a single SR product, in reducing DENV infection and active Aedes-borne virus (ABV) disease in human cohorts.
- Trial name
- AEGIS ABV (NCT05452447)
- Testing
- Transfluthrin
- Where
- 2 sites in Sri Lanka
- Volunteers
- 6,949 people, healthy volunteers welcome
- Sponsor
- University of Notre Dame
Dengue Fever
A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico)
This is a first time in humans (FTiH) study designed to assess the experimental TDENV-PIV vaccine in a predominantly dengue-primed adult population.
- Trial name
- DPIV-002 (NCT01702857)
- Testing
- Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant, Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant, Phosphate buffered saline
- Where
- Puerto Rico
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue Fever
Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose
The purpose of this study is to describe antibody persistence for each of the 4 dengue serotypes for up to 63 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-315…
- Trial name
- NCT03999996
- Testing
- Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)
- Where
- 10 sites in United States, Mexico
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- Takeda